Stoke Therapeutics Inc (NAS:STOK)

$ 13.05 -0.05 (-0.38%) Market Cap: 690.88 Mil Enterprise Value: 409.98 Mil PE Ratio: 0 PB Ratio: 2.81 GF Score: 40/100

Stoke Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2024
Stoke Therapeutics Inc Extraordinary Shareholders Meeting Transcript
Oct 24, 2023
Stoke Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Sep 26, 2023
Stoke Therapeutics Inc at Canaccord Genuity Growth Conference Transcript
Aug 09, 2023
Stoke Therapeutics Inc to Present the Analysis of STK-001 for the Treatment of Dravet Syndrome Transcript
Jul 25, 2023
Stoke Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 13, 2023
Stoke Therapeutics Inc at Bank of America Global Healthcare Conference Transcript
May 11, 2023
Stoke Therapeutics Inc at Needham Neuroscience Forum (Virtual) Transcript
Mar 15, 2023
Stoke Therapeutics Inc at Cowen Health Care Conference Transcript
Mar 06, 2023
Stoke Therapeutics Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript
Feb 14, 2023
Stoke Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2023
Stoke Therapeutics Inc STK-001 Call Transcript
Nov 14, 2022
Stoke Therapeutics Inc Annual Shareholders Meeting Transcript
Jul 07, 2022
Stoke Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 12, 2022
Stoke Therapeutics Inc at Cowen Health Care Conference (Virtual) Transcript
Mar 07, 2022
Stoke Therapeutics Inc To Present Interim Data From MONARCH Study In Dravet Syndrome Interim Analysis Call Transcript
Sep 21, 2021
Stoke Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 08, 2021
Stoke Therapeutics Inc at UBS Global Healthcare Virtual Conference Transcript
May 24, 2021

Stoke Therapeutics Inc To Present Interim Data From MONARCH Study In Dravet Syndrome Interim Analysis Call Transcript

Sep 21, 2021 / 12:30PM GMT

Release Date Price: $25 (+5.71%)

Transcript

Operator

Ladies and gentlemen, thank you for standing by and welcome to Stoke Therapeutics MONARCH Study and Dravet Syndrome Interim Analysis. (Operator Instructions) I will now return the call over to your host. Eric Rojas. You may begin.

Eric Rojas

Stoke Therapeutics - VP, Head of IR

Thank you, Kevin and good morning. This is Eric Rojas, Head of Investor Relations with Stoke Therapeutics. On today's call, we will discuss results from the interim analysis of the Phase 1/2a clinical study of our investigational medicine STK-001 for the treatment of Dravet syndrome. Our speakers today is Dr. Edward Kaye, Stoke's CEO, and Dr. Barry Ticho, Stoke's Chief Medical Officer.

As you listen to this call, we recommend that you access the webcast slides and the investors section on our website. This call is being recorded and a replay will also be available on the Stoke website later today. We will make forward-looking statements on this call that is subject to the risks and uncertainties discussed in detail in today's press release, and then our filings with the

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.